ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 104 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,915 | -57.6% | 4,774 | -33.7% | 0.00% | – |
| Q2 2023 | $54,049 | -50.3% | 7,197 | -70.1% | 0.00% | – |
| Q1 2023 | $108,674 | -60.6% | 24,043 | -1.8% | 0.00% | – |
| Q4 2022 | $275,923 | +18.9% | 24,483 | +1.1% | 0.00% | – |
| Q3 2022 | $232,000 | +17.2% | 24,220 | -1.1% | 0.00% | – |
| Q2 2022 | $198,000 | -19.5% | 24,490 | +68.2% | 0.00% | – |
| Q1 2022 | $246,000 | -30.5% | 14,557 | -11.7% | 0.00% | – |
| Q4 2021 | $354,000 | -70.4% | 16,495 | +2.0% | 0.00% | -100.0% |
| Q3 2021 | $1,194,000 | -10.7% | 16,170 | -33.9% | 0.00% | 0.0% |
| Q2 2021 | $1,337,000 | -31.1% | 24,452 | -7.1% | 0.00% | -33.3% |
| Q1 2021 | $1,940,000 | +52.9% | 26,315 | +78.7% | 0.00% | +50.0% |
| Q4 2020 | $1,269,000 | +132.0% | 14,725 | +1.6% | 0.00% | +100.0% |
| Q3 2020 | $547,000 | – | 14,486 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
| Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
| Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
| Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
| Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
| BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
| Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
| Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
| Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
| CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |